PLA2G6 Gene (PARK14) Parkinson's Genetic Test in Dubai, UAE | NGS Analysis

Executive Summary & Core Metrics

✓ Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 15189 accredited Next-Generation Sequencing (NGS) with uniform coverage of the entire PLA2G6 gene coding region and splice sites.
✓ Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM across all UAE emirates.
✓ Clinical Guidance: Complimentary telephonic post-test genetic counselling provided by a DHA-licensed consultant medical geneticist for comprehensive result interpretation.
✓ Insurance & Billing: Direct billing verification available via WhatsApp at +971 54 548 8731.

Test Overview & Methodology

The PLA2G6 gene NGS test provides comprehensive analysis of the entire coding sequence and flanking intronic regions for PARK14-related early-onset Parkinson's disease. This advanced sequencing platform detects single-nucleotide variants, small insertions and deletions, and copy-number variations with exceptional sensitivity and specificity, surpassing traditional Sanger sequencing in both breadth and depth of coverage.

Feature	Our PLA2G6 NGS Test	Closest Alternative (Sanger Sequencing)
Precision	99.9% analytical sensitivity with uniform coverage across all exons and intron-exon boundaries	~95% for targeted exons; may miss deep intronic or structural variants
Methodology	Next-Generation Sequencing (NGS) – full gene, flanking regions, and CNV detection	Capillary electrophoresis; limited to pre-defined amplicons
Turnaround Time	3–4 Weeks	4–6 Weeks
Regulatory Compliance	UAE PDPL, Federal Law No. 2 of 2019, DHA Licensing Standards	May not include mandatory genetic counselling mandate
Price	2,800 AED	Approx. 3,200 AED

Physician Insight & Safety Protocols

“Genetic testing for PLA2G6 must always be interpreted alongside a complete clinical evaluation, detailed family history, and neurological assessment. A positive result indicates increased susceptibility to early-onset Parkinson's disease and does not represent a definitive diagnosis. A negative result does not rule out other genetic or idiopathic causes of parkinsonism. Comprehensive pre- and post-test genetic counselling is essential to discuss inheritance patterns, implications for at-risk family members, and potential management strategies.”

— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

Advisory Clinical Guidance

Do not discontinue, alter, or initiate any prescribed medication based solely on genetic test results without direct consultation with your treating neurologist or movement disorder specialist. Genetic results are one component of a comprehensive diagnostic workup and should never replace clinical judgment.

Patient Safety & Exclusion Criteria

Exclusion: This test is not intended for asymptomatic minors. Genetic testing for Parkinson's disease susceptibility in children requires specialist paediatric neurology and medical genetics evaluation with appropriate ethical oversight.
Exclusion: This test is not a standalone diagnostic tool and must be ordered and interpreted by a qualified physician in conjunction with clinical findings and family history.
Red Flag: If you experience severe depression, suicidal ideation, acute confusion, or rapid neurological deterioration after receiving genetic test results, seek immediate emergency medical care by calling 998 or visiting the nearest emergency department.

Patient FAQ & Clinical Guidance

1. What is the PLA2G6 PARK14 genetic test?

The PLA2G6 gene NGS test screens the entire coding region and flanking intronic sequences for pathogenic variants associated with early-onset Parkinson's disease (PARK14) and neurodegeneration with brain iron accumulation (NBIA type 2B). It is the most comprehensive molecular method available to detect single-nucleotide variants, indels, and copy-number changes within the PLA2G6 gene. Genetic counselling before and after testing is strongly recommended to understand inheritance patterns, penetrance, and implications for biological family members.

2. How long does the PLA2G6 genetic test take to deliver results?

The complete testing process requires 3 to 4 weeks from sample receipt to final validated report. This timeline encompasses genomic DNA extraction, library preparation, NGS sequencing on an Illumina platform, bioinformatics alignment and variant calling, rigorous quality control, variant classification according to ACMG/AMP guidelines, and final interpretive review by a consultant clinical molecular geneticist. Results are delivered through a secure online portal and accompanied by a telephonic counselling session.

3. Is home collection available for this genetic test in the UAE?

Yes, hospital-grade VIP mobile phlebotomy and temperature-controlled cold-chain home collection is available daily from 8 AM to 11 PM across all seven emirates. A certified phlebotomist will collect a peripheral whole blood sample or a dried blood spot on an FTA card under strict cold-chain protocols to ensure nucleic acid integrity. Advance booking is required via WhatsApp at +971 54 548 8731. All sample logistics comply fully with UAE PDPL data privacy and health data protection regulations under Federal Law No. 2 of 2019.

UAE Regulatory & Data Privacy Adherence

Your genetic data is protected under the stringent framework of Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All clinical testing and patient consent procedures comply with Federal Decree-Law No. 4 of 2016 on Medical Liability. DNA Labs UAE is a DHA-licensed facility (License No. 1143) operating under ISO 15189 accredited processes. Your genomic information is encrypted, access-controlled, and never shared with third parties without your explicit written consent.

Clinical & Logistical Metadata

Test Name	PLA2G6 Gene (PARK14) Parkinson's Genetic Test – NGS Full Gene Sequencing
Price (AED)	2,800 AED
Turnaround Time	3–4 Weeks
Sample Type / Matrix	Peripheral Whole Blood (EDTA tube) or Dried Blood Spot (FTA card)
Methodology Used	Next-Generation Sequencing (NGS) – Full Gene Coding Region, Splice Sites & CNV Detection
ICD-10-CM Code	G20 (Parkinson's Disease), E75.5 (Neurodegeneration with Brain Iron Accumulation)
LOINC Code	83259-8 (PLA2G6 gene mutation analysis in Blood by Molecular genetics method Sequencing)
DHA Facility License & Address	DHA License No. 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| DNA Labs UAE